Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2432 (LINC02432) is a long non-coding RNA implicated in the regulation of cancer cell metabolism, particularly in pancreatic adenocarcinoma. As part of a regulatory axis with miR-98-5p and HK2, LINC02432 promotes glycolysis and suppresses ferroptosis, thereby enhancing tumor cell proliferation and survival. Its expression is correlated with immune infiltration and tumor mutation burden, highlighting its role as a risk stratification marker and potential therapeutic target. Elevated LINC02432 suggests a worse prognosis, and patients with high expression may show increased sensitivity to certain kinase inhibitors[2][4].
Acts as a competing endogenous RNA (ceRNA) by sponging miR-98-5p, leading to upregulation of HK2 and enhanced glycolytic activity in cancer cells; disruption of ferroptosis; modulation of immune cell infiltration and chemokine expression
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2432 (LINC02432).